Difference between revisions of "Longhaul Covid19"
m |
m (→References) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
* The emerging data and anecdotal evidence of long term recovery and persistent debilitating symptoms highlight the need for robust, standardised studies to assess the risk of and risk factors for consequences after COVID -19 infection. The ISARIC study aims to establish a longitudinal cohort of patients with COVID -19 post-discharge, to characterize the risk of long-term consequences and immune response over time in different populations globally. <ref name="ISARIC2020">Sigfrid, L., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., Drake, T. M., ... & Kildal, A. What is the recovery rate and risk of long-term consequences from COVID-19?-A harmonised, global observational study protocol.</ref> | * The emerging data and anecdotal evidence of long term recovery and persistent debilitating symptoms highlight the need for robust, standardised studies to assess the risk of and risk factors for consequences after COVID -19 infection. The ISARIC study aims to establish a longitudinal cohort of patients with COVID -19 post-discharge, to characterize the risk of long-term consequences and immune response over time in different populations globally. <ref name="ISARIC2020">Sigfrid, L., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., Drake, T. M., ... & Kildal, A. What is the recovery rate and risk of long-term consequences from COVID-19?-A harmonised, global observational study protocol.</ref> | ||
| + | |||
| + | * The Covid-19 symptom tracking app developed at King’s College London, which has been downloaded by 3.9 million people globally to date, has reported that 10% people had symptoms at 25 days and 5% were still ill one month later. <ref name="Rayner2020">Clare Rayner C, Lokug amage A, Molokhia M. Covid 19: Prolonged and relapsing | ||
| + | course of illness has implications for returning workers BMJ. 2020.</ref> | ||
==Observations== | ==Observations== | ||
==Analysis and interpretation== | ==Analysis and interpretation== | ||
| + | * SARS-CoV-2 is a very novel virus, only reportedly appearing in the human population at the end of 2019, which means there is still much that the medical and wider research community do not know. To solve this, well-conducted long term research is needed<ref name="Mahase2020">Mahase, E. (2020). Covid-19: What do we know about “long covid”?. bmj, 370.</ref>, not just on hospitalised COVID19 patients, but on a representative sample of all infected individuals. | ||
==Consequences for action== | ==Consequences for action== | ||
| Line 17: | Line 21: | ||
=References= | =References= | ||
| − | </ | + | <references/> |
Latest revision as of 14:24, 1 September 2020
This page collects observations, interpretations, and consequences for action about Long-term COVID19 sequellae. Please observe the structure of the page, when you add your content. Please use references where possible. Remember to find the relevant page. For example, if your observation is about transmission routes, please use that page, instead of posting your content here.
Contents
Long-haul COVID19
What is already known
- Among 143 COVID19 patients that were followed-up after discharge, only 18 (12.6%) were completely free of any COVID-19–related symptom when assessed on average 60.3 days after disease onset. Of those who were still symptomatic, 32% had 1 or 2 symptoms and 55% had 3 or more. The most common persistent symptoms were fatigue and dyspnoea. Worsened quality of life was observed among 44.1% of patients. [1]
- Patients with severe COVID-19 disease typically experience sequelae affecting their respiratory status, physical health and mental health for at least several weeks after hospital discharge. [2]
- The emerging data and anecdotal evidence of long term recovery and persistent debilitating symptoms highlight the need for robust, standardised studies to assess the risk of and risk factors for consequences after COVID -19 infection. The ISARIC study aims to establish a longitudinal cohort of patients with COVID -19 post-discharge, to characterize the risk of long-term consequences and immune response over time in different populations globally. [3]
- The Covid-19 symptom tracking app developed at King’s College London, which has been downloaded by 3.9 million people globally to date, has reported that 10% people had symptoms at 25 days and 5% were still ill one month later. [4]
Observations
Analysis and interpretation
- SARS-CoV-2 is a very novel virus, only reportedly appearing in the human population at the end of 2019, which means there is still much that the medical and wider research community do not know. To solve this, well-conducted long term research is needed[5], not just on hospitalised COVID19 patients, but on a representative sample of all infected individuals.
Consequences for action
References
- ↑ Carfì, A., Bernabei, R., & Landi, F. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA.
- ↑ Weerahandi, H., Hochman, K. A., Simon, E., Blaum, C., Chodosh, J., Duan, E., ... & Mendoza, F. (2020). Post-discharge health status and symptoms in patients with severe COVID-19. medRxiv.
- ↑ Sigfrid, L., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., Drake, T. M., ... & Kildal, A. What is the recovery rate and risk of long-term consequences from COVID-19?-A harmonised, global observational study protocol.
- ↑ Clare Rayner C, Lokug amage A, Molokhia M. Covid 19: Prolonged and relapsing course of illness has implications for returning workers BMJ. 2020.
- ↑ Mahase, E. (2020). Covid-19: What do we know about “long covid”?. bmj, 370.
